Commenting on the CPGs, EASL Secretary General Professor Markus Peck - Radosavljevic said «EASL is dedicated to
promoting hepatology research and education to improve the worldwide treatment of liver disease.
In the future, a Patient - on - a-Chip also could be used to predict how a disease progresses in an individual, allowing for the design of personalized preventive medicine and treatment regimens to
promote wellness and prevent disease, said Robert Barrett, PhD, an assistant professor of Medicine at Cedars - Sinai and senior author of the study in Cellular and Molecular Gastroenterology and
Hepatology.